The Hollings Cancer Center at the Medical University of South Carolina is a National Cancer Institute-designated cancer center and the largest academic-based cancer research program in South Carolina. The cancer center comprises more than 120 faculty cancer scientists with an annual research funding portfolio of $44 million and a dedication to reducing the cancer burden in South Carolina. Hollings offers state-of-the-art diagnostic capabilities, therapies and surgical techniques within multidisciplinary clinics that include surgeons, medical oncologists, radiation therapists, radiologists, pathologists, psychologists and other specialists equipped for the full range of cancer care, including more than 200 clinical trials.
Featured Videos |view more
Study of advanced glycation end produces (AGEs) through dietary and exercise intervention to see if improvement of quality of life decreases tumor recurrence in patients.
Thanks to improved treatments, patients with cancer are living longer. Some of those treatments, however, are associated with cardiotoxicities that can put patients at risk for heart problems.
Raymond N. DuBois MD, dean of the College of Medicine at the Medical University of South Carolina discusses Stand Up to Cancer’s Catalyst Program.
This video features surgical photos from a recent case of nipple-sparing mastectomy followed by pre-pectoral breast reconstruction at MUSC Hollings Cancer Center.
The first robotic DIEP flap harvest was performed in February 2017 at MUSC Health by plastic surgeon Kevin O. Delaney, M.D.,and robotic surgeon Rana C. Pullatt, M.D., who directs the robotic surgery program for the Department of Surgery.
Featured Documents |view more
As part of MUSC's growing transnational genomics program, a genomics tumor board has been created to bring diverse specialists together to help physicians diagnose and manage cancer.
Transanal total mesorectal excision (TaTME) has garnered a great surgery because it represents a reversal of perspective—literally— about how best to excise tumors and the surrounding mesorectal envelope in the lower third of the rectum.
Researchers are using adoptive cell transfer (ACT) to reinforce the ranks of a patient’s own T cells—the body’s warriors—and train them to better target the patient’s cancer.
News that novel T cell–based immunotherapeutic approaches such as immune checkpoint blockade and adoptive cell transfer are achieving durable responses in patients with aggressive cancers has created excitement in the world of cancer research.
Genomics screening can improve the odds for some cancer patients, potentially identifying mutations associated with cancer subtypes for which targeted therapies exist or are in development.
All content found on this Website, including: video, text, images, audio, or other formats were created for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have seen or read on this Website. If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately. MUSC does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on this website. Reliance on any information provided by this website, MUSC employees, contracted writers, or medical professionals presenting content for publication to MUSC is solely at your own risk. The Site may contain health- or medical-related materials or discussions regarding graphic images, and sexually explicit disease states. If you find these materials offensive, you may not want to use our Site. The Site and its Content are provided on an "as is" basis. Links to educational content not created by MUSC are taken at your own risk. MUSC is not responsible for the claims of external websites and companies.